10018617

Welcome to STN International! Enter x:x

LOGINID:ssspta1623hrr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

10018617

FILE 'HOME' ENTERED AT 15:55:27 ON 10 MAY 2002

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:55:37 ON 10 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 8 MAY 2002 HIGHEST RN 412906-88-8
DICTIONARY FILE UPDATES: 8 MAY 2002 HIGHEST RN 412906-88-8

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2076

L1 SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10018617.str

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> d l2
L2 HAS NO ANSWERS
L2 STR



10018617

Structure attributes must be viewed using STN Express query preparation.

```
=> s l2
SAMPLE SEARCH INITIATED 15:56:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     75 TO ITERATE

100.0% PROCESSED      75 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          981 TO     2019
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L2

=> s l3
SAMPLE SEARCH INITIATED 15:56:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     75 TO ITERATE

100.0% PROCESSED      75 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          981 TO     2019
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L2 AND L1

=> s l1 full
FULL SEARCH INITIATED 15:56:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED                        400000 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:            0 TO        0
PROJECTED ANSWERS:         EXCEEDS 1000000

L6       400000 SEA SSS FUL L1

=> s l2 full
FULL SEARCH INITIATED 15:56:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1535 TO ITERATE

100.0% PROCESSED    1535 ITERATIONS                               8 ANSWERS
SEARCH TIME: 00.00.01

L7            8 SEA SSS FUL L2

=> s l3 full
FULL SEARCH INITIATED 15:56:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1535 TO ITERATE
```

10018617

100.0% PROCESSED 1535 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L8 8 SEA SSS FUL L2 AND L1

=> d l8

L8 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-27-3 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with 1-butanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Butanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1) (9CI)
MF C16 H30 O5 . C4 H10 O . Ca
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 71-36-3
CMF C4 H10 O



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d 1-8 l7

L7 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-27-3 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with 1-butanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Butanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1) (9CI)
MF C16 H30 O5 . C4 H10 O . Ca
SR CA
LC STN Files: CA, CAPLUS

10018617

CM 1

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 71-36-3
CMF C4 H10 O



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-26-2 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with 2-propanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Propanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1)
(9CI)
MF C16 H30 O5 . C3 H8 O . Ca
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 67-63-0
CMF C3 H8 O

10018617



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-25-1 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with 1-propanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1-Propanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1)
(9CI)
MF C16 H30 O5 . C3 H8 O . Ca
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 71-23-8
CMF C3 H8 O



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-24-0 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with methanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Methanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1) (9CI)
MF C16 H30 O5 . C H4 O . Ca
SR CA
LC STN Files: CA, CAPLUS

CM 1

10018617

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 67-56-1
CMF C H4 O



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-23-9 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt, compd. with ethanol (1:1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanol, compd. with calcium 6,6'-oxybis[2,2-dimethylhexanoate] (1:1:1) (9CI)
MF C16 H30 O5 . C2 H6 O . Ca
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 183293-82-5
CMF C16 H30 O5



CM 2

CRN 64-17-5
CMF C2 H6 O



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 351011-22-8 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt (1:1), monohydrate (9CI) (CA INDEX NAME)
MF C16 H30 O5 . Ca . H2 O
SR CA
LC STN Files: CA, CAPLUS
CRN (183293-82-5)



● Ca

● H_2O

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 209789-08-2 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl-, calcium salt (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CI 1027
CN Gemcabene calcium
CN PD 0072953
MF C16 H30 O5 . Ca
SR CAS Registry Services
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (183293-82-5)



● Ca

6 REFERENCES IN FILE CA (1967 TO DATE)

10018617

6 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2002 ACS
RN 183293-82-5 REGISTRY
CN Hexanoic acid, 6,6'-oxybis[2,2-dimethyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN PD 72953
FS 3D CONCORD
MF C16 H30 O5
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	435.44	435.65

FILE 'CAPLUS' ENTERED AT 15:58:05 ON 10 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 May 2002 VOL 136 ISS 19
FILE LAST UPDATED: 8 May 2002 (20020508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use

the CAS Roles thesaurus (/RL field) in this file.

```
=> s l8
L9          11 L8

=> d 1-11 l9

L9   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2002 ACS
AN   2002:71865  CAPLUS
DN   136:112665
TI   Treatment of eating disorders using carboxyalkyl ethers
IN   Auerbach, Bruce Jeffrey; Butler, Donald Eugene
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 12 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2002005807      A1   20020124       WO 2001-US16334  20010518
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
             RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
             UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-218399P   P    20000714
OS   MARPAT 136:112665
RE.CNT  7     THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9   ANSWER 2 OF 11  CAPLUS  COPYRIGHT 2002 ACS
AN   2001:903813  CAPLUS
DN   136:15239
TI   Carboxyalkyl ether-ACAT inhibitor combinations
IN   Auerbach, Bruce Jeffrey; Zobel, Donna Lee
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 18 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2001093845      A2   20011213       WO 2001-US14804  20010508
         W:  AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM,
             DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK,
             LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SI, SK, SL,
             TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-210056P   P    20000607
```

10018617

OS MARPAT 136:15239

L9 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2001:798043 CAPLUS
DN 135:339248
TI Antihypertensive agents comprising carboxyalkylethers
IN Auerbach, Bruce Jeffrey; Hitchcock, Karen Diane; Ryan, Michael John
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080847	A2	20011101	WO 2001-US9088	20010322

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-199855P P 20000426
US 2000-242280P P 20001020
OS MARPAT 135:339248

L9 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2001:564976 CAPLUS
DN 135:122200
TI Preparation and characterization of alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
for the treatment of dyslipidemia, vascular disease and diabetes
IN Ando, Howard Yoshihisa; Butler, Donald Eugene; Dozeman, Gary Jay
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001055078	A1	20010802	WO 2001-IB26	20010111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-177823P P 20000125
OS MARPAT 135:122200
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10018617

L9 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2000:227499 CAPLUS
DN 132:260690
TI Method using cholesterol-lowering agents for preventing or delaying catheter-based revascularization
IN Black, Donald Michael
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018395	A1	20000406	WO 1999-US15385	19990708
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949750	A1	20000417	AU 1999-49750	19990708
	EP 1117392	A1	20010725	EP 1999-933763	19990708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9914098	A	20010731	BR 1999-14098	19990708
	NO 2001001615	A	20010424	NO 2001-1615	20010329
PRAI	US 1998-102457P	P	19980930		
	WO 1999-US15385	W	19990708		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:495161 CAPLUS
DN 131:125474
TI Method for treating Alzheimer's disease with agents lowering plasma triglycerides and optional hypocholesterolemic agents
IN Bisgaier, Charles Larry; Emmerling, Mark Richard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938498	A1	19990805	WO 1998-US25495	19981202
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2311356	AA	19990805	CA 1998-2311356	19981202
	AU 9916165	A1	19990816	AU 1999-16165	19981202

	BR 9814923	A	20001017	BR 1998-14923	19981202
	EP 1051161	A1	20001115	EP 1998-960605	19981202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002501887	T2	20020122	JP 2000-529231	19981202
	US 2002055529	A1	20020509	US 2001-888592	20010626
PRAI	US 1998-72912P	P	19980128		
	WO 1998-US25495	W	19981202		
	US 2000-554994	A3	20000523		

OS MARPAT 131:125474
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:404834 CAPLUS
DN 131:49492
TI Statin-carboxyalkylether combinations for treating vascular diseases
IN Bisgaier, Charles Larry; Newton, Roger Schofield
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9930704	A1	19990624	WO 1998-US24679	19981120
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2304612	AA	19990624	CA 1998-2304612	19981120
	AU 9915915	A1	19990705	AU 1999-15915	19981120
	BR 9813542	A	20001010	BR 1998-13542	19981120
	EP 1045691	A1	20001025	EP 1998-960278	19981120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002508320	T2	20020319	JP 2000-538687	19981120
	ZA 9811348	A	19990614	ZA 1998-11348	19981210
	NO 2000002966	A	20000609	NO 2000-2966	20000609
PRAI	US 1997-69375P	P	19971212		
	WO 1998-US24679	W	19981120		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:124309 CAPLUS
DN 130:305969
TI Automated solid-phase extraction workstations combined with quantitative bioanalytical LC/MS
AU Huang, N. Helen; Kagel, John R.; Rossi, David T.
CS Bioanalytical Core Group, Department of Pharmacokinetics and Dynamics, Metabolism, Division of Warner-Lambert, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA
SO Journal of Pharmaceutical and Biomedical Analysis (1999), 19(3-4), 613-620

CODEN: JPBADA; ISSN: 0731-7085
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1998:374795 CAPLUS
DN 129:62727
TI A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. [Erratum to document cited in CA128:213102]
AU Bisgaier, Charles L.; Essenburg, Arnold D.; Barnett, Blake C.; Auerbach, Bruce J.; Haubenwallner, Sabine; Leff, Todd; White, Andrew D.; Creger, Paul; Pape, Michael E.; Rea, Thomas J.; Newton, Roger S.
CS Division of Warner-Lambert Company, Departments of VAscular and Cardiac Diseases, Ann Arbor, MI, 48105, USA
SO J. Lipid Res. (1998), 39(6), 1317
CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English

L9 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1998:61642 CAPLUS
DN 128:213102
TI A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor
AU Bisgaier, Charles L.; Essenburg, Arnold D.; Barnett, Blake C.; Auerbach, Bruce J.; Haubenwallner, Sabine; Leff, Todd; White, Andrew D.; Creger, Paul; Pape, Michael E.; Rea, Thomas J.; Newton, Roger S.
CS Division of Warner-Lambert Company, Departments of Vascular and Cardiac Diseases, Ann Arbor, MI, 48105, USA
SO J. Lipid Res. (1998), 39(1), 17-30
CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English

L9 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1996:689457 CAPLUS
DN 125:328104
TI Preparation of terminal carboxy or tetrazole group-containing dialkyl ethers as anticholesteremics and antidiabetics
IN Bisgaier, Charles Larry; Creger, Paul Leroy; Saltiel, Alan Robert; Tafuri, Sherrie Rae
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9630328	A1	19961003	WO 1996-US1639	19960205

W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT,

```
            LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ
        RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT
    US 5648387          A    19970715       US 1995-409780   19950324
    CA 2215233          AA   19961003       CA 1996-2215233  19960205
    AU 9647768          A1   19961016       AU 1996-47768    19960205
    AU 692359           B2   19980604
    EP 820428           A1   19980128       EP 1996-903794   19960205
    EP 820428           B1   20000510
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV
    CN 1182415          A    19980520       CN 1996-193500   19960205
    JP 11502532         T2   19990302       JP 1996-529342   19960205
    AT 192732           E    20000515       AT 1996-903794   19960205
    ES 2148733          T3   20001016       ES 1996-903794   19960205
    PL 181673           B1   20010831       PL 1996-322407   19960205
    CZ 289556           B6   20020213       CZ 1997-2922     19960205
    ZA 9602275          A    19960930       ZA 1996-2275     19960320
    US 5750569          A    19980512       US 1997-805533   19970225
    US 5756544          A    19980526       US 1997-806582   19970225
    US 5783600          A    19980721       US 1997-806580   19970225
    FI 9703713          A    19970924       FI 1997-3713     19970917
    NO 9704397          A    19971120       NO 1997-4397     19970923
PRAI US 1995-409780     A    19950324
    WO 1996-US1639      W    19960205
OS  MARPAT 125:328104


=> d 1-11 19 bib abs 19
L9 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> d bib abs 1-11 19

L9  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2002 ACS
AN  2002:71865  CAPLUS
DN  136:112665
TI  Treatment of eating disorders using carboxyalkyl ethers
IN  Auerbach, Bruce Jeffrey; Butler, Donald Eugene
PA  Warner-Lambert Company, USA
SO  PCT Int. Appl., 12 pp.
    CODEN: PIXXD2
DT  Patent
LA  English
FAN.CNT 1
    PATENT NO.          KIND  DATE           APPLICATION NO.  DATE
    ----------------    ----  --------       ---------------  --------
PI  WO 2002005807       A1    20020124       WO 2001-US16334  20010518
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
            UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
            BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-218399P    P     20000714
OS  MARPAT 136:112665
```

AB Carboxyalkylethers, e.g. 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid, are useful for treating eating disorders, e.g. obesity.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2001:903813 CAPLUS
DN 136:15239
TI Carboxyalkyl ether-ACAT inhibitor combinations
IN Auerbach, Bruce Jeffrey; Zobel, Donna Lee
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001093845	A2	20011213	WO 2001-US14804	20010508

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-210056P P 20000607
OS MARPAT 136:15239
AB A pharmaceutical compn. comprising (i) a carboxyalkyl ether which lowers triglycerides and LDL and elevates HDL, and (ii) an ACAT inhibitor which improves dyslipidemias in mammals, useful for treating dyslipidemia and ischemic syndromes, and for preventing or delaying the onset of heart attacks is described. A ACAT inhibitor is [(2,4,6-triisopropylphenyl)acetyl]sulfamic acid 6-diisopropylphenyl ester (CI-1011) and a carboxyalkyl ether is 6,6'-oxybis(2,2-dimethylhexanoic acid) or its calcium salt. For example, the lipid modifying and antiatherosclerotic action of CI-1011, CI-1027, and the combination of both compds. was assessed in a rabbit cuff model of atherosclerosis.

L9 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2001:798043 CAPLUS
DN 135:339248
TI Antihypertensive agents comprising carboxyalkylethers
IN Auerbach, Bruce Jeffrey; Hitchcock, Karen Diane; Ryan, Michael John
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080847	A2	20011101	WO 2001-US9088	20010322

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL,

TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-199855P P 20000426
US 2000-242280P P 20001020
OS MARPAT 135:339248
AB The invention is a pharmaceutical compn. comprising a carboxyalkylether of the formula Y1(R1)(R2)C (CH2)nO(CH2)mC(R3)(R4)Y2 wherein R1, R2, R3, and R4 include alkyl, alkenyl, and alkynyl, m and n are integers from 2 to 9, Y1 and Y2 include COOH, CHO, tetrazole, COOR5 where R5 is alkyl, alkenyl, or alkynyl, or a pharmaceutically acceptable salt thereof, and an antihypertensive agent, said compn. being useful for treating vascular diseases. The invention includes a method of treating hypertension comprising administering a carboxyalkylether. Antihypertensive effect of CI-1027 in combination with quinapril was shown in rats.

L9 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2001:564976 CAPLUS
DN 135:122200
TI Preparation and characterization of alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt for the treatment of dyslipidemia, vascular disease and diabetes
IN Ando, Howard Yoshihisa; Butler, Donald Eugene; Dozeman, Gary Jay
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055078	A1	20010802	WO 2001-IB26	20010111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 2000-177823P P 20000125
OS MARPAT 135:122200
AB Alc. and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt are prepd. which are cryst. and have the formula -O2CC(CH3)2(CH2)4O(CH2)4CO2-.Ca2+.xR1OH (I; R1 = H, lower alkyl, x = 0-10) [e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid monocalcium salt 1-Pr alc. solvate] and are useful for treating dyslipidemia, diabetes, and vascular disease; I-contg. formulations are presented.
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10018617

L9 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 2000:227499 CAPLUS
DN 132:260690
TI Method using cholesterol-lowering agents for preventing or delaying catheter-based revascularization
IN Black, Donald Michael
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000018395	A1	20000406	WO 1999-US15385	19990708
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949750	A1	20000417	AU 1999-49750	19990708
	EP 1117392	A1	20010725	EP 1999-933763	19990708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9914098	A	20010731	BR 1999-14098	19990708
	NO 2001001615	A	20010424	NO 2001-1615	20010329
PRAI	US 1998-102457P	P	19980930		
	WO 1999-US15385	W	19990708		

AB Aggressively lowering cholesterol in patients suffering from coronary artery disease prevents or delays the need for catheter-based revascularization. A cholesterol-lowering agent, e.g. an HMG-CoA reductase inhibitor such as atorvastatin, is used in an amt. effective to cause an aggressive lowering of LDL cholesterol.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:495161 CAPLUS
DN 131:125474
TI Method for treating Alzheimer's disease with agents lowering plasma triglycerides and optional hypocholesterolemic agents
IN Bisgaier, Charles Larry; Emmerling, Mark Richard
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938498	A1	19990805	WO 1998-US25495	19981202
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2311356	AA	19990805	CA 1998-2311356	19981202
	AU 9916165	A1	19990816	AU 1999-16165	19981202
	BR 9814923	A	20001017	BR 1998-14923	19981202
	EP 1051161	A1	20001115	EP 1998-960605	19981202
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002501887	T2	20020122	JP 2000-529231	19981202
	US 2002055529	A1	20020509	US 2001-888592	20010626
PRAI	US 1998-72912P	P	19980128		
	WO 1998-US25495	W	19981202		
	US 2000-554994	A3	20000523		

OS MARPAT 131:125474

AB A method for treating or preventing the onset of Alzheimer's Disease comprises administering to a mammal in need thereof an Alzheimer's Disease-preventing or -treating amt. of a plasma triglyceride level-lowering agent. Optionally, the plasma triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent. The relationship between Alzheimer's disease and known risk factors for cardiovascular disease was also studied.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:404834 CAPLUS
DN 131:49492
TI Statin-carboxyalkylether combinations for treating vascular diseases
IN Bisgaier, Charles Larry; Newton, Roger Schofield
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9930704	A1	19990624	WO 1998-US24679	19981120
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2304612	AA	19990624	CA 1998-2304612	19981120
	AU 9915915	A1	19990705	AU 1999-15915	19981120
	BR 9813542	A	20001010	BR 1998-13542	19981120
	EP 1045691	A1	20001025	EP 1998-960278	19981120
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002508320	T2	20020319	JP 2000-538687	19981120
	ZA 9811348	A	19990614	ZA 1998-11348	19981210
	NO 2000002966	A	20000609	NO 2000-2966	20000609
PRAI	US 1997-69375P	P	19971212		
	WO 1998-US24679	W	19981120		

AB The invention is a pharmaceutical compn. comprising a carboxyalkylether

which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said compn. being useful for treating vascular diseases. Rats were fed with high cholesterol chow diet and were given 10 mg/kg of 6-6'-oxybis-(2,2-dimethylhexanoic acid calcium salt) and 30 mg/kg of atorvastatin calcium for 14 days. The triglyceride level and HDL/VLDL+LDL was 63 and 2.59 as compared with 118 mg/dL, and 2.59, resp., for the controls.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1999:124309 CAPLUS
DN 130:305969
TI Automated solid-phase extraction workstations combined with quantitative bioanalytical LC/MS
AU Huang, N. Helen; Kagel, John R.; Rossi, David T.
CS Bioanalytical Core Group, Department of Pharmacokinetics and Dynamics, Metabolism, Division of Warner-Lambert, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA
SO Journal of Pharmaceutical and Biomedical Analysis (1999), 19(3-4), 613-620
CODEN: JPBADA; ISSN: 0731-7085
PB Elsevier Science B.V.
DT Journal
LA English
AB An automated solid-phase extn. workstation was used to develop, characterize and validate an LC/MS/MS method for quantifying a novel lipid-regulating drug in dog plasma, i.e. PD 072953. Method development was facilitated by workstation functions that allowed wash solvents of varying org. compn. to be mixed and tested automatically. Precision ests. for this approach were within 9.8% relative std. deviation (RSD) across the calibration range. Accuracy for replicate detns. of quality controls was between -7.2 and +6.2% relative error (RE) over 5-1000 ng mL-1. Recoveries were evaluated for a wide variety of wash solvents, elution solvents and sorbents. Optimized recoveries were generally >95%. A sample throughput benchmark for the method was .apprxeq. 8 min per sample. Because of parallel sample processing, 100 samples were extd. in less than 120 min. The approach has proven useful for use with LC/MS/MS, using a multiple reaction monitoring (MRM) approach.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1998:374795 CAPLUS
DN 129:62727
TI A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. [Erratum to document cited in CA128:213102]
AU Bisgaier, Charles L.; Essenburg, Arnold D.; Barnett, Blake C.; Auerbach, Bruce J.; Haubenwallner, Sabine; Leff, Todd; White, Andrew D.; Creger, Paul; Pape, Michael E.; Rea, Thomas J.; Newton, Roger S.
CS Division of Warner-Lambert Company, Departments of VAscular and Cardiac Diseases, Ann Arbor, MI, 48105, USA
SO J. Lipid Res. (1998), 39(6), 1317

10018617

CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English
AB In the first column of Table 1, headed "Plasma Determinant," "ApoC-I" should be "ApoC-II.". The cor. Table 1 is given.

L9 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1998:61642 CAPLUS
DN 128:213102
TI A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor
AU Bisgaier, Charles L.; Essenburg, Arnold D.; Barnett, Blake C.; Auerbach, Bruce J.; Haubenwallner, Sabine; Leff, Todd; White, Andrew D.; Creger, Paul; Pape, Michael E.; Rea, Thomas J.; Newton, Roger S.
CS Division of Warner-Lambert Company, Departments of Vascular and Cardiac Diseases, Ann Arbor, MI, 48105, USA
SO J. Lipid Res. (1998), 39(1), 17-30
CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English
AB In the current studies, the authors describe the effects of PD 72953 and related compds. on lipoprotein levels in chow-fed male rats. After 2 wk, 10 mg/kg of PD 72953 daily was as effective as 100 mg/kg gemfibrozil for elevating HDL-cholesterol. At 100 mg/kg, PD 72953 further elevated HDL-cholesterol to 232% of control levels, and was assocd. with increased HDL size and plasma apoE (169% of control), despite no change in hepatic apoE mRNA. ApoA-I rose transiently (at 1 wk), but by 2 wk only apoE remained elevated. PD 72953 dose-dependently reduced plasma apoB, VLDL-cholesterol, LDL-cholesterol, and triglyceride. Hepatic apoC-III mRNA redn. paralleled triglyceride lowering. After 1 wk, 30 and 100 mg/kg per day PD 72953 reduced plasma apoC-III levels by 30 and 34%, and triglycerides by 60 and 83%, resp. PD 72953 treatment had no effect on triglyceride prodn. rates; however, 125I-labeled VLDL apoB disappearance was enhanced. The authors compared PD 72953 to a structurally similarly diacid, PD 69405, that also reduced VLDL and LDL, but had no effect on HDL elevation. Compared to PD 72953, PD 69405 further accelerated 125I-labeled VLDL apoB disappearance, decreased triglyceride prodn., and elevated the ratio of post-heparin hepatic to lipoprotein lipase activity.
Whole animal studies, transient transfection studies in HepG2 cells, and chimeric receptor studies in kidney 293 cells suggest that PD 72953 is a ligand for the peroxisomal proliferation activated receptor alpha (PPAR.alpha.), and PPAR.gamma.. Overall, PD 72953 may act through a peroxisomal proliferation-activated receptor and result in plasma triglycerides and apoB-contg. lipoprotein redn., while also raising HDL cholesterol. Reduced apoC-III may allow triglyceride-rich remnants to more efficiently bind and present substrate to peripheral tissue lipoprotein lipase, and therefore allow enhanced shedding of remnant phospholipid surface for HDL prodn.

L9 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2002 ACS
AN 1996:689457 CAPLUS
DN 125:328104
TI Preparation of terminal carboxy or tetrazole group-containing dialkyl

10018617

ethers as anticholesteremics and antidiabetics
IN Bisgaier, Charles Larry; Creger, Paul Leroy; Saltiel, Alan Robert; Tafuri, Sherrie Rae
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9630328	A1	19961003	WO 1996-US1639	19960205
	W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT				
	US 5648387	A	19970715	US 1995-409780	19950324
	CA 2215233	AA	19961003	CA 1996-2215233	19960205
	AU 9647768	A1	19961016	AU 1996-47768	19960205
	AU 692359	B2	19980604		
	EP 820428	A1	19980128	EP 1996-903794	19960205
	EP 820428	B1	20000510		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
	CN 1182415	A	19980520	CN 1996-193500	19960205
	JP 11502532	T2	19990302	JP 1996-529342	19960205
	AT 192732	E	20000515	AT 1996-903794	19960205
	ES 2148733	T3	20001016	ES 1996-903794	19960205
	PL 181673	B1	20010831	PL 1996-322407	19960205
	CZ 289556	B6	20020213	CZ 1997-2922	19960205
	ZA 9602275	A	19960930	ZA 1996-2275	19960320
	US 5750569	A	19980512	US 1997-805533	19970225
	US 5756544	A	19980526	US 1997-806582	19970225
	US 5783600	A	19980721	US 1997-806580	19970225
	FI 9703713	A	19970924	FI 1997-3713	19970917
	NO 9704397	A	19971120	NO 1997-4397	19970923
PRAI	US 1995-409780	A	19950324		
	WO 1996-US1639	W	19960205		

OS MARPAT 125:328104
AB The title compds. Y1(R1)(R2)C(CH2)nO(CH2)mC(R3)(R4)Y2 [I; R1-R4 = alkyl, alkenyl, alkynyl; Y1, Y2 = CO2H, CHO, tetrazole, (un)substituted carboxylate ester; m, n = 2-9], which lower Lp(a) and triglycerides and elevate HDL-cholesterol, useful for treating vascular diseases and noninsulin-dependent diabetes mellitus, are prepd. and I-contg. formulations presented. Thus, isobutyric acid was reacted with 4,4'-dichlorobutyl ether in the presence of (MeHC)2 and NaH, producing 6,6'-oxybis(2,2-dimethylhexanoic acid), m.p. 49-51.degree., which demonstrated anticholesteremic activity.

=> s l9 and diabetes
68497 DIABETES
L10 2 L9 AND DIABETES

=> d 1-2 l10

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 2001:564976 CAPLUS

10018617

DN 135:122200
TI Preparation and characterization of alcohol and water solvates of 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
for the treatment of dyslipidemia, vascular disease and **diabetes**
IN Ando, Howard Yoshihisa; Butler, Donald Eugene; Dozeman, Gary Jay
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001055078	A1	20010802	WO 2001-IB26	20010111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-177823P P 20000125
OS MARPAT 135:122200
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 1996:689457 CAPLUS
DN 125:328104
TI Preparation of terminal carboxy or tetrazole group-containing dialkyl ethers as anticholesteremics and antidiabetics
IN Bisgaier, Charles Larry; Creger, Paul Leroy; Saltiel, Alan Robert; Tafuri,
Sherrie Rae
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9630328	A1	19961003	WO 1996-US1639	19960205

W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT

US 5648387	A	19970715	US 1995-409780	19950324
CA 2215233	AA	19961003	CA 1996-2215233	19960205
AU 9647768	A1	19961016	AU 1996-47768	19960205
AU 692359	B2	19980604		
EP 820428	A1	19980128	EP 1996-903794	19960205
EP 820428	B1	20000510		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV

CN 1182415	A	19980520	CN 1996-193500	19960205

10018617

	JP 11502532	T2	19990302	JP 1996-529342	19960205
	AT 192732	E	20000515	AT 1996-903794	19960205
	ES 2148733	T3	20001016	ES 1996-903794	19960205
	PL 181673	B1	20010831	PL 1996-322407	19960205
	CZ 289556	B6	20020213	CZ 1997-2922	19960205
	ZA 9602275	A	19960930	ZA 1996-2275	19960320
	US 5750569	A	19980512	US 1997-805533	19970225
	US 5756544	A	19980526	US 1997-806582	19970225
	US 5783600	A	19980721	US 1997-806580	19970225
	FI 9703713	A	19970924	FI 1997-3713	19970917
	NO 9704397	A	19971120	NO 1997-4397	19970923
PRAI	US 1995-409780	A	19950324		
	WO 1996-US1639	W	19960205		
OS	MARPAT 125:328104				